Mundima yesainzi yezvizorwa, DL panthenol yakafanana nekiyi inovhura musuwo wehutano hweganda. Iyi precursor yevhitamini B5, ine yakanakisa kunyorova, kugadzirisa, uye anti-kuzvimba mhedzisiro, yave chinhu chinonyanya kukosha chinoshanda mune skincare mafomula. Ichi chinyorwa chichaongorora zvakavanzika zvesainzi, kukosha kwekushandisa, uye tarisiro yeramangwana yeDL panthenol.
1, Scientific decoding yeDL panthenol
DL panthenol imhando yerudzi rwepanthenol, ine zita remakemikari 2,4-dihydroxy-N - (3-hydroxypropyl) -3,3-dimethylbutanamide. Chimiro chayo chemorekuru chine boka rekutanga doro uye mapoka maviri echipiri edoro, ayo anoiisa yakanakisa hydrophilicity uye permeability.
Iyo nzira yekutendeuka muganda ndiyo kiyi yekubudirira kweDL panthenol. Mushure mekupinda mukati meganda, DL panthenol inokurumidza kuchinjwa kuva pantothenic acid (vitamini B5), iyo inotora chikamu mukugadzirwa kwecoenzyme A, nokudaro inokanganisa fatty acid metabolism uye kuwedzera kwesero. Tsvagiridzo yakaratidza kuti kutendeuka kweDL panthenol muepidermis kunogona kusvika 85%.
Iyo huru nzira yekuita inosanganisira kusimudzira ganda barriers basa, kukurudzira epithelial cell kuwanda, uye inhibiting kuzvimba mhinduro. Data yekuongorora inoratidza kuti mushure mekushandisa chigadzirwa chine 5% DL panthenol kwemavhiki mana, kupera kwemvura yeganda kunoderedzwa ne40%, uye kuvimbika kwe stratum corneum kunovandudzwa zvikuru.
2、 Multidimensional application yeDL panthenol
Mumunda wekunyorovesa, DL panthenol inowedzera hydration ye stratum corneum uye inowedzera hunyoro hweganda. Miedzo yemakiriniki yakaratidza kuti kushandisa moisturizer ine DL panthenol kwemaawa masere kunowedzera hunyoro hweganda ne50%.
Panyaya yekugadzirisa, DL panthenol inogona kukurudzira epidermal cell kuwanda uye nekumhanyisa barriers basa kupora. Tsvagiridzo yakaratidza kuti postoperative kushandiswa kwezvigadzirwa zvine DL panthenol zvinogona kupfupisa nguva yekupora maronda ne30%.
Nekuchengetedza tsandanyama, DL panthenol's anti-kuzvimba uye inonyaradza mhedzisiro inonyanya kutaridzika. Ongororo dzakaratidza kuti DL panthenol inogona kudzivisa kusunungurwa kwezvinhu zvinoputika zvakadai seIL-6 uye TNF - α, kuderedza ganda rakatsvuka uye kutsamwa.
Mukuchengetwa kwebvudzi, DL panthenol inogona kupinda mukati mebvudzi uye kugadzirisa keratin yakakuvadzwa. Mushure mekushandisa zvigadzirwa zvekuchengetedza bvudzi zvine DL panthenol kwemavhiki gumi nemaviri, simba rekutsemuka kwebvudzi rakawedzera ne35% uye kupenya kwakavandudzwa ne40%.
3. Ramangwana tarisiro yeDL panthenol
Mitsva yekugadzira matekinoroji senge nanocarriers uye liposomes yakavandudza zvakanyanya kugadzikana uye bioavailability yeDL panthenol. Semuenzaniso, nanoemulsions inogona kuwedzera kupenya kweganda kweDL panthenol ne2 nguva.
Clinical application research inoramba ichidzika. Tsvagiridzo yazvino inoratidza kuti DL panthenol ine mukana wekukosha mukurapa adjuvant yezvirwere zveganda senge atopic dermatitis uye psoriasis. Semuyenzaniso, kushandiswa kweDL panthenol ine maforomations muvarwere vane atopic dermatitis kunogona kuderedza itching scores ne50%.
Tarisiro yemusika yakakura. Zvinotarisirwa kuti panosvika 2025, musika wepasi rose weDL panthenol unosvika 350 miriyoni emadhora ekuAmerica, nekukura kwepagore kweanopfuura 8%. Nekuwedzera kuri kuda kwezvinyoro zvinoshanda zvinongedzo kubva kune vatengi, nzvimbo dzekushandisa dzeDL panthenol dzichawedzera kuwedzera.
Kuwanikwa uye kushandiswa kweDL panthenol kwakavhura nguva nyowani yekutarisira ganda. Kubva pakunyorovesa nekugadzirisa kusvika kune-anti-kuzvimba uye kunyaradza, kubva pakutarisisa kwechiso kusvika pakutarisirwa kwemuviri, ichi chinhu chinoshanda chakawanda chiri kushandura maonero edu ehutano hweganda. Mune ramangwana, nekufambira mberi kwekugadzira tekinoroji uye kudzika kwekutsvagisa kwekiriniki, DL panthenol pasina mubvunzo ichaunza humwe hutsva uye mikana yekuchengeta ganda. Panzira yekutsvaga kunaka uye hutano, DL panthenol icharamba ichiita basa rayo rakasiyana uye rinokosha, kunyora chitsauko chitsva musayenzi yeganda.
Nguva yekutumira: Mar-18-2025
